AiSentia - The next generation of contrast-enhanced imaging in computerised tomography (CT)

AiSentia是牛津大学的一个分支，由一个世界级的团队组成，提供创新的医疗解决方案，支持患者护理。AiSentia的目标是利用人工智能(AI)开发下一代临床成像技术，以支持血管的临床决策。这款由人工智能驱动的专有软件能够显著改变最佳实践，在降低医疗成本的同时改善患者的体验和结果。计算机断层扫描(CT)是一种诊断成像程序，它使用X射线照射到对象(如人体)上，生成对象目标区域的横断面图像，有时被称为“切片”。对比剂的引入有助于将身体选定的区域与周围组织区分开来，或将其与周围组织进行对比，这可以用来诊断特定的情况。但对于一些可能需要反复去医院就诊的患者来说，反复暴露在X光下是不可取的，可能会损害他们的健康。此外，由于碘化造影剂限制了医生使用先进成像诊断潜在问题的能力，一些患者还容易出现过敏性休克、糖尿病症状或造影剂诱发的肾病。除了患者的好处外，碘化造影剂还会在接下来的24小时内排入医院厕所或家庭厕所，进入废水。碘很难从废水中去除，而且对环境有害。AiSens的目标是消除用于CT成像的碘化造影剂，并通过减少废水系统中释放的生物制药废物量来改善环境。该项目试图通过开发一种突破性的软件来帮助这些患者、医院和环境，这意味着无需为患者注射造影剂就可以常规使用CTA扫描。一旦开发出来，AiSania有望通过打开新市场、创造收入和投资来改善患者的整体结果和护理标准，从而产生革命性的效果，从而有利于英国的经济和可持续发展。

AiSentia is a spin-out from the University of Oxford consisting of a world-class team that delivers innovative healthcare solutions that champion patient care.AiSentia's aim is to develop next generation clinical imaging technologies using Artificial Intelligence (AI) to support clinical decision-making on blood vessels. The proprietary AI-driven software has the ability to dramatically change best practice, reducing healthcare costs whilst improving the patient's experience and outcomes.A computerised tomography (CT) scan is a diagnostic imaging procedure which uses x-rays impinging on a subject, such as the human body, to produce cross-sectional images, sometimes called 'slices', of a targeted region of the subject. The introduction of a contrast agent helps distinguish or "contrast" selected areas of the body from the surrounding tissue, which can be used to diagnose specific conditions.However, for some patients who may require repeated hospital visits, the repeated exposure to X-rays is undesirable and may be detrimental to their health. Furthermore, some patients are also susceptible to anaphylactic shock, diabetic symptoms, or contrast induced nephropathy due to iodinated contrast which limits the ability for their doctors to use advanced imaging to diagnose potential issues.In addition to the patient benefits, iodinated contrast media are excreted into the hospital toilets or home toilets over the next 24 hours entering the wastewater. Iodine is difficult to remove from the wastewater and is detrimental to the environment. The aim of AiSentia is to eliminate iodinated contrast media for CT imaging and improve the environment by reducing the amount of biopharmaceutical waste released in the wastewater system.This project seeks to help these patients, the hospitals, and the environment by developing a ground-breaking software that means that CTA scans could be used routinely without patients having to be injected with contrast agents.Once developed, AiSentia is expected to improve overall patient outcomes and standard-of-care delivering transformative effects by opening new markets, generating revenues and investment which benefits the UK economy and sustainability.